A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer

Clinton Yam, Elizabeth A. Mittendorf, Haven R. Garber, Ryan Sun, Senthil Damodaran, Rashmi K. Murthy, David Ramirez, Meghan Karuturi, Rachel M. Layman, Nuhad Ibrahim, Gaiane M. Rauch, Beatriz E. Adrada, Rosalind P. Candelaria, Jason B. White, Elizabeth Ravenberg, Alyson Clayborn, Qing Qing Ding, W. Fraser Symmans, Sabitha Prabhakaran, Alastair M. ThompsonVicente Valero, Debu Tripathy, Lei Huo, Stacy L. Moulder, Jennifer K. Litton

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Fingerprint

Dive into the research topics of 'A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences